A Phase 2 Study of Sorafenib in Combination with Cetuximab in EGFR-expressing, KRAS-mutated Metastatic Colorectal Cancer

BACKGROUND: Mutations in the KRAS gene predict for resistance to anti-EGFR therapies, including cetuximab. Upregulation of VEGF-A has been implicated in resistance to anti-EGFR treatment. Abrogation of the VEGF and RAS/RAF/MEK/ERK pathways has the potential to restore cetuximab sensitivity. PATIENTS...

全面介紹

Na minha lista:
書目詳細資料
發表在:Clin Colorectal Cancer
Main Authors: Do, Khanh, Cao, Liang, Kang, Zhigang, Turkbey, Baris, Lindenberg, Maria L., Larkins, Erin, Holkova, Beata, Steinberg, Seth M., Raffeld, Mark, Peer, Cody J., Figg, William D., Eugeni, Michelle, Jacobs, Paula, Choyke, Peter, Wright, John J., Doroshow, James H., Kummar, Shivaani
格式: Artigo
語言:Inglês
出版: 2015
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6657351/
https://ncbi.nlm.nih.gov/pubmed/25861837
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clcc.2015.02.007
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍